Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
1070 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Pancreatic Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Pancreatic Cancer - Pipeline Review, H2 2014', provides an overview of the Pancreatic Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 10 Pancreatic Cancer Overview 11 Therapeutics Development 12 Pancreatic Cancer - Therapeutics under Development by Companies 14 Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 31 Pancreatic Cancer - Pipeline Products Glance 35 Pancreatic Cancer - Products under Development by Companies 39 Pancreatic Cancer - Products under Investigation by Universities/Institutes 60 Pancreatic Cancer - Companies Involved in Therapeutics Development 64 Pancreatic Cancer - Therapeutics Assessment 266 Drug Profiles 300 Pancreatic Cancer - Recent Pipeline Updates 811 Pancreatic Cancer - Dormant Projects 1006 Pancreatic Cancer - Discontinued Products 1021 Pancreatic Cancer - Product Development Milestones 1023 Appendix 1030
List of Tables Number of Products under Development for Pancreatic Cancer, H2 2014 51 Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2014 52 Number of Products under Development by Companies, H2 2014 54 Number of Products under Development by Companies, H2 2014 (Contd..1) 55 Number of Products under Development by Companies, H2 2014 (Contd..2) 56 Number of Products under Development by Companies, H2 2014 (Contd..3) 57 Number of Products under Development by Companies, H2 2014 (Contd..4) 58 Number of Products under Development by Companies, H2 2014 (Contd..5) 59 Number of Products under Development by Companies, H2 2014 (Contd..6) 60 Number of Products under Development by Companies, H2 2014 (Contd..7) 61 Number of Products under Development by Companies, H2 2014 (Contd..8) 62 Number of Products under Development by Companies, H2 2014 (Contd..9) 63 Number of Products under Development by Companies, H2 2014 (Contd..10) 64 Number of Products under Development by Companies, H2 2014 (Contd..11) 65 Number of Products under Development by Companies, H2 2014 (Contd..12) 66 Number of Products under Development by Companies, H2 2014 (Contd..13) 67 Number of Products under Development by Companies, H2 2014 (Contd..14) 68 Number of Products under Development by Companies, H2 2014 (Contd..15) 69 Number of Products under Investigation by Universities/Institutes, H2 2014 71 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 72 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 73 Comparative Analysis by Late Stage Development, H2 2014 74 Comparative Analysis by Clinical Stage Development, H2 2014 75 Comparative Analysis by Early Stage Development, H2 2014 76 Comparative Analysis by Unknown Stage Development, H2 2014 77 Products under Development by Companies, H2 2014 78 Products under Development by Companies, H2 2014 (Contd..1) 79 Products under Development by Companies, H2 2014 (Contd..2) 80 Products under Development by Companies, H2 2014 (Contd..3) 81 Products under Development by Companies, H2 2014 (Contd..4) 82 Products under Development by Companies, H2 2014 (Contd..5) 83 Products under Development by Companies, H2 2014 (Contd..6) 84 Products under Development by Companies, H2 2014 (Contd..7) 85 Products under Development by Companies, H2 2014 (Contd..8) 86 Products under Development by Companies, H2 2014 (Contd..9) 87 Products under Development by Companies, H2 2014 (Contd..10) 88 Products under Development by Companies, H2 2014 (Contd..11) 89 Products under Development by Companies, H2 2014 (Contd..12) 90 Products under Development by Companies, H2 2014 (Contd..13) 91 Products under Development by Companies, H2 2014 (Contd..14) 92 Products under Development by Companies, H2 2014 (Contd..15) 93 Products under Development by Companies, H2 2014 (Contd..16) 94 Products under Development by Companies, H2 2014 (Contd..17) 95 Products under Development by Companies, H2 2014 (Contd..18) 96 Products under Development by Companies, H2 2014 (Contd..19) 97 Products under Development by Companies, H2 2014 (Contd..20) 98 Products under Investigation by Universities/Institutes, H2 2014 99 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 100 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 101 Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 102 Pancreatic Cancer - Pipeline by 3-V Biosciences, Inc., H2 2014 103 Pancreatic Cancer - Pipeline by 3B Pharmaceuticals GmbH, H2 2014 104 Pancreatic Cancer - Pipeline by 4SC AG, H2 2014 105 Pancreatic Cancer - Pipeline by AB Science, H2 2014 106 Pancreatic Cancer - Pipeline by AbGenomics International, Inc., H2 2014 107 Pancreatic Cancer - Pipeline by Ability Pharma, SL, H2 2014 108 Pancreatic Cancer - Pipeline by Adamed Sp. z o.o., H2 2014 109 Pancreatic Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H2 2014 110 Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H2 2014 111 Pancreatic Cancer - Pipeline by Advantagene, Inc., H2 2014 112 Pancreatic Cancer - Pipeline by Advaxis, Inc., H2 2014 113 Pancreatic Cancer - Pipeline by AIMM Therapeutics B.V., H2 2014 114 Pancreatic Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2014 115 Pancreatic Cancer - Pipeline by Almac Discovery Ltd., H2 2014 116 Pancreatic Cancer - Pipeline by Ambrx, Inc., H2 2014 117 Pancreatic Cancer - Pipeline by Ambryx Biotechnology, Inc., H2 2014 118 Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp., H2 2014 119 Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2014 120 Pancreatic Cancer - Pipeline by Apexigen, Inc., H2 2014 121 Pancreatic Cancer - Pipeline by Aphios Corporation, H2 2014 122 Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H2 2014 123 Pancreatic Cancer - Pipeline by Aposense Ltd., H2 2014 124 Pancreatic Cancer - Pipeline by Aptose Biosciences Inc., H2 2014 125 Pancreatic Cancer - Pipeline by Arch Biopartners, Inc., H2 2014 126 Pancreatic Cancer - Pipeline by Argon Pharma S.L., H2 2014 127 Pancreatic Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2014 128 Pancreatic Cancer - Pipeline by Astellas Pharma Inc., H2 2014 129 Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Limited, H2 2014 130 Pancreatic Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014 131 Pancreatic Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2014 132 Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 133 Pancreatic Cancer - Pipeline by Bayer AG, H2 2014 134 Pancreatic Cancer - Pipeline by BerGenBio AS, H2 2014 135 Pancreatic Cancer - Pipeline by Beta Pharma, Inc., H2 2014 136 Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals, LLC., H2 2014 137 Pancreatic Cancer - Pipeline by BioCancell Therapeutics, Inc., H2 2014 138 Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H2 2014 139 Pancreatic Cancer - Pipeline by BioMarin Pharmaceutical Inc., H2 2014 140 Pancreatic Cancer - Pipeline by Bioncotech Therapeutics S.L., H2 2014 141 Pancreatic Cancer - Pipeline by Bionomics Limited, H2 2014 142 Pancreatic Cancer - Pipeline by BiOrion Technologies B.V., H2 2014 143 Pancreatic Cancer - Pipeline by Biotest AG, H2 2014 144 Pancreatic Cancer - Pipeline by Biothera, Inc., H2 2014 145 Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 146 Pancreatic Cancer - Pipeline by Cavion LLC, H2 2014 147 Pancreatic Cancer - Pipeline by cCAM Biotherapeutics Ltd., H2 2014 148 Pancreatic Cancer - Pipeline by Celgene Corporation, H2 2014 149 Pancreatic Cancer - Pipeline by Cellectis S.A., H2 2014 150 Pancreatic Cancer - Pipeline by Celsion Corporation, H2 2014 151 Pancreatic Cancer - Pipeline by Ceronco Biosciences, H2 2014 152 Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H2 2014 153 Pancreatic Cancer - Pipeline by Confluence Life Sciences, Inc., H2 2014 154 Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2014 155 Pancreatic Cancer - Pipeline by CritiTech, Inc., H2 2014 156 Pancreatic Cancer - Pipeline by CrystalGenomics, Inc., H2 2014 157 Pancreatic Cancer - Pipeline by CureFAKtor Pharmaceuticals. LLC, H2 2014 158 Pancreatic Cancer - Pipeline by CureTech Ltd., H2 2014 159 Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2014 160 Pancreatic Cancer - Pipeline by CytomX Therapeutics, Inc., H2 2014 161 Pancreatic Cancer - Pipeline by CytoVac A/S, H2 2014 162 Pancreatic Cancer - Pipeline by CZ BioMed Corp, H2 2014 163 Pancreatic Cancer - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 164 Pancreatic Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 165 Pancreatic Cancer - Pipeline by DEKK-TEC, Inc., H2 2014 166 Pancreatic Cancer - Pipeline by DiaMedica Inc., H2 2014 167 Pancreatic Cancer - Pipeline by Erytech Pharma SA, H2 2014 168 Pancreatic Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2014 169 Pancreatic Cancer - Pipeline by Etubics Corporation, H2 2014 170 Pancreatic Cancer - Pipeline by Exelixis, Inc., H2 2014 171 Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 172 Pancreatic Cancer - Pipeline by Fujifilm Corporation, H2 2014 173 Pancreatic Cancer - Pipeline by Fusion Antibodies Ltd, H2 2014 174 Pancreatic Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2014 175 Pancreatic Cancer - Pipeline by Genelux Corporation, H2 2014 176 Pancreatic Cancer - Pipeline by Genentech, Inc., H2 2014 177 Pancreatic Cancer - Pipeline by Genmab A/S, H2 2014 178 Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H2 2014 179 Pancreatic Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 180 Pancreatic Cancer - Pipeline by Globeimmune, Inc., H2 2014 181 Pancreatic Cancer - Pipeline by Heat Biologics, Inc., H2 2014 182 Pancreatic Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2014 183 Pancreatic Cancer - Pipeline by Huabo Biopharm Co., Ltd., H2 2014 184 Pancreatic Cancer - Pipeline by Hutchison MediPharma Limited, H2 2014 185 Pancreatic Cancer - Pipeline by iCeutica, Inc., H2 2014 186 Pancreatic Cancer - Pipeline by Ignyta, Inc., H2 2014 187 Pancreatic Cancer - Pipeline by IkerChem S.L., H2 2014 188 Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H2 2014 189 Pancreatic Cancer - Pipeline by Immune Pharmaceuticals, Inc., H2 2014 190 Pancreatic Cancer - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2014 191 Pancreatic Cancer - Pipeline by Immunomedics, Inc., H2 2014 192 Pancreatic Cancer - Pipeline by Immunovative Therapies, Ltd., H2 2014 193 Pancreatic Cancer - Pipeline by Immunovo BV, H2 2014 194 Pancreatic Cancer - Pipeline by Immutep S.A., H2 2014 195 Pancreatic Cancer - Pipeline by IMPACT Therapeutics, Inc., H2 2014 196 Pancreatic Cancer - Pipeline by Incuron, LLC, H2 2014 197 Pancreatic Cancer - Pipeline by Innopharmax Inc., H2 2014 198 Pancreatic Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 199 Pancreatic Cancer - Pipeline by Intezyne, Inc, H2 2014 200 Pancreatic Cancer - Pipeline by Intica Biomedical, Inc., H2 2014 201 Pancreatic Cancer - Pipeline by InvivoGen Therapeutics, H2 2014 202 Pancreatic Cancer - Pipeline by Io Therapeutics, Inc., H2 2014 203 Pancreatic Cancer - Pipeline by Isarna Therapeutics GmbH, H2 2014 204 Pancreatic Cancer - Pipeline by iTeos Therapeutics SA, H2 2014 205 Pancreatic Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H2 2014 206 Pancreatic Cancer - Pipeline by Kadmon Corporation, LLC, H2 2014 207 Pancreatic Cancer - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 208 Pancreatic Cancer - Pipeline by Kalos Therapeutics, Inc., H2 2014 209 Pancreatic Cancer - Pipeline by Kancera AB, H2 2014 210 Pancreatic Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 211 Pancreatic Cancer - Pipeline by Keystone Nano, Inc., H2 2014 212 Pancreatic Cancer - Pipeline by Lipopharma Therapeutics SL, H2 2014 213 Pancreatic Cancer - Pipeline by LivTech, Inc., H2 2014 214 Pancreatic Cancer - Pipeline by MabVax Therapeutics, Inc., H2 2014 215 Pancreatic Cancer - Pipeline by Meabco A/S, H2 2014 216 Pancreatic Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2014 217 Pancreatic Cancer - Pipeline by MediaPharma s.r.l., H2 2014 218 Pancreatic Cancer - Pipeline by Medivation, Inc., H2 2014 219 Pancreatic Cancer - Pipeline by Merck & Co., Inc., H2 2014 220 Pancreatic Cancer - Pipeline by Merck KGaA, H2 2014 221 Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 222 Pancreatic Cancer - Pipeline by Morphotek, Inc., H2 2014 223 Pancreatic Cancer - Pipeline by MSM Protein Technologies, Inc., H2 2014 224 Pancreatic Cancer - Pipeline by Multimmune GmbH, H2 2014 225 Pancreatic Cancer - Pipeline by Nanobiotix, H2 2014 226 Pancreatic Cancer - Pipeline by Natco Pharma Limited, H2 2014 227 Pancreatic Cancer - Pipeline by NeoPharm Co., Ltd., H2 2014 228 Pancreatic Cancer - Pipeline by NewLink Genetics Corporation, H2 2014 229 Pancreatic Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2014 230 Pancreatic Cancer - Pipeline by Novartis AG, H2 2014 231 Pancreatic Cancer - Pipeline by NuCana BioMed Limited, H2 2014 232 Pancreatic Cancer - Pipeline by Nuvilex, Inc., H2 2014 233 Pancreatic Cancer - Pipeline by Omeros Corporation, H2 2014 234 Pancreatic Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2014 235 Pancreatic Cancer - Pipeline by Oncodesign SA, H2 2014 236 Pancreatic Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2014 237 Pancreatic Cancer - Pipeline by Oncology Research International Limited, H2 2014 238 Pancreatic Cancer - Pipeline by Oncomatrix, S.L., H2 2014 239 Pancreatic Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2014 240 Pancreatic Cancer - Pipeline by Oncothyreon Inc., H2 2014 241 Pancreatic Cancer - Pipeline by Oncovir, Inc., H2 2014 242 Pancreatic Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 243 Pancreatic Cancer - Pipeline by Optimum Therapeutics, LLC, H2 2014 244 Pancreatic Cancer - Pipeline by Oscotec Inc., H2 2014 245 Pancreatic Cancer - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 246 Pancreatic Cancer - Pipeline by Patrys Limited, H2 2014 247 Pancreatic Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 248 Pancreatic Cancer - Pipeline by Pfizer Inc., H2 2014 249 Pancreatic Cancer - Pipeline by Pharma Two B Ltd, H2 2014 250 Pancreatic Cancer - Pipeline by PharmAbcine, Inc., H2 2014 251 Pancreatic Cancer - Pipeline by Pharmacyclics, Inc., H2 2014 252 Pancreatic Cancer - Pipeline by Pharmedartis GmbH, H2 2014 253 Pancreatic Cancer - Pipeline by Pharminox Limited, H2 2014 254 Pancreatic Cancer - Pipeline by Philogen S.p.A., H2 2014 255 Pancreatic Cancer - Pipeline by Phoenix Biotechnology, Inc., H2 2014 256 Pancreatic Cancer - Pipeline by Pique Therapeutics, H2 2014 257 Pancreatic Cancer - Pipeline by Piramal Enterprises Limited, H2 2014 258 Pancreatic Cancer - Pipeline by Plexxikon Inc., H2 2014 259 Pancreatic Cancer - Pipeline by Polaris Group, H2 2014 260 Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H2 2014 261 Pancreatic Cancer - Pipeline by Priaxon AG, H2 2014 262 Pancreatic Cancer - Pipeline by Prima BioMed Ltd., H2 2014 263 Pancreatic Cancer - Pipeline by Qu Biologics Inc., H2 2014 264 Pancreatic Cancer - Pipeline by Quantum Pharmaceuticals, H2 2014 265 Pancreatic Cancer - Pipeline by Quest PharmaTech Inc., H2 2014 266 Pancreatic Cancer - Pipeline by Quintessence Biosciences, Inc., H2 2014 267 Pancreatic Cancer - Pipeline by Regulon Inc., H2 2014 268 Pancreatic Cancer - Pipeline by RESprotect GmbH, H2 2014 269 Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2014 270 Pancreatic Cancer - Pipeline by Rigontec GmbH, H2 2014 271 Pancreatic Cancer - Pipeline by Sanofi, H2 2014 272 Pancreatic Cancer - Pipeline by Sareum Holdings plc, H2 2014 273 Pancreatic Cancer - Pipeline by SignPath Pharma Inc, H2 2014 274 Pancreatic Cancer - Pipeline by Solasia Pharma K.K., H2 2014 275 Pancreatic Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2014 276 Pancreatic Cancer - Pipeline by Symphogen A/S, H2 2014 277 Pancreatic Cancer - Pipeline by Synovo GmbH, H2 2014 278 Pancreatic Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 279 Pancreatic Cancer - Pipeline by Tactic Pharma, LLC, H2 2014 280 Pancreatic Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2014 281 Pancreatic Cancer - Pipeline by Takara Bio Inc., H2 2014 282 Pancreatic Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 283 Pancreatic Cancer - Pipeline by Targovax AS, H2 2014 284 Pancreatic Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2014 285 Pancreatic Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 286 Pancreatic Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 287 Pancreatic Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 288 Pancreatic Cancer - Pipeline by TransTech Pharma, Inc., H2 2014 289 Pancreatic Cancer - Pipeline by TVAX Biomedical, Inc., H2 2014 290 Pancreatic Cancer - Pipeline by Tyg Oncology Ltd, H2 2014 291 Pancreatic Cancer - Pipeline by Valens Therapeutics, Inc., H2 2014 292 Pancreatic Cancer - Pipeline by ValiRx Plc, H2 2014 293 Pancreatic Cancer - Pipeline by Vaxeal Holding SA, H2 2014 294 Pancreatic Cancer - Pipeline by Vaximm AG, H2 2014 295 Pancreatic Cancer - Pipeline by Vaxon Biotech, H2 2014 296 Pancreatic Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 297 Pancreatic Cancer - Pipeline by Virax Holdings Limited, H2 2014 298 Pancreatic Cancer - Pipeline by Virobay Inc., H2 2014 299 Pancreatic Cancer - Pipeline by Welichem Biotech Inc., H2 2014 300 Pancreatic Cancer - Pipeline by Wilex AG, H2 2014 301 Pancreatic Cancer - Pipeline by Yuhan Corporation, H2 2014 302 Pancreatic Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2014 303 Pancreatic Cancer - Pipeline by Zymeworks Inc., H2 2014 304 Assessment by Monotherapy Products, H2 2014 305 Assessment by Combination Products, H2 2014 306 Number of Products by Stage and Target, H2 2014 308 Number of Products by Stage and Mechanism of Action, H2 2014 325 Number of Products by Stage and Route of Administration, H2 2014 336 Number of Products by Stage and Molecule Type, H2 2014 338 Pancreatic Cancer Therapeutics - Recent Pipeline Updates, H2 2014 850 Pancreatic Cancer - Dormant Projects, H2 2014 1045 Pancreatic Cancer - Dormant Projects (Contd..1), H2 2014 1046 Pancreatic Cancer - Dormant Projects (Contd..2), H2 2014 1047 Pancreatic Cancer - Dormant Projects (Contd..3), H2 2014 1048 Pancreatic Cancer - Dormant Projects (Contd..4), H2 2014 1049 Pancreatic Cancer - Dormant Projects (Contd..5), H2 2014 1050 Pancreatic Cancer - Dormant Projects (Contd..6), H2 2014 1051 Pancreatic Cancer - Dormant Projects (Contd..7), H2 2014 1052 Pancreatic Cancer - Dormant Projects (Contd..8), H2 2014 1053 Pancreatic Cancer - Dormant Projects (Contd..9), H2 2014 1054 Pancreatic Cancer - Dormant Projects (Contd..10), H2 2014 1055 Pancreatic Cancer - Dormant Projects (Contd..11), H2 2014 1056 Pancreatic Cancer - Dormant Projects (Contd..12), H2 2014 1057 Pancreatic Cancer - Dormant Projects (Contd..13), H2 2014 1058 Pancreatic Cancer - Dormant Projects (Contd..14), H2 2014 1059 Pancreatic Cancer - Discontinued Products, H2 2014 1060 Pancreatic Cancer - Discontinued Products (Contd..1), H2 2014 1061
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
